Table 3.

Geometric mean (% coefficient of variation) of telatinib and BAY 60-8246 pharmacokinetic parameters on day 14 of cycle 1

Parameter	Telatinib dose
	600 mg bid (n = 6)	900 mg bid (n = 27)	1200 mg bid (n = 2) 1500 mg bid (n = 4) (n = 6)
Telatinib
Cmax (mg/l)	0.825 (93%)	0.899 (91%) b	1.467 (33%)
Tmax (h) a	2.3 [1.1 - 4]	2.6 [0.5 - 8] b	2.5 [0.67 - 4.1]
AUC(0-tn) (mg·h/l)	5.779 (71%)	5.547 (80%) b	9.244 (31%)
AUC(0-12) (mg·h/l)	5.779 (71%)	5.761 (82%) b	9.800 (33%)
Half-life (h)	8.2 (47%)	6.8 (47%) c	8.1 (71%)
BAY 60-8246
Cmax (mg/l)	0.101 (203%)	0.095 (120%)	0.207 (85%)
Tmax (h) a	2.3 [0.6 - 4]	3.2 [0.5 - 12.2]	2.6 [0.5 - 4.1]
AUC(0-tn) (mg·h/l)	0.826 (181%)	0.634 (101%)	1.499 (93%)
AUC(0-12) (mg·h/l)	0.826 (182%)	0.636 (101%) d	1.595 (92%)
Half-life (h)	6.2 (14%) d	6.5 (48%) e	7.8 (38%) b

- AUC_{(0-12) -} area under the plasma concentration versus time curve from time 0 to 12 hours

- AUC_{(0-tn) -} area under the plasma concentration versus time curve from time 0 to last data point

- Bid - bis in die, twice daily

- C_{max -} maximum plasma concentration

- T_{max -} time to reach maximum plasma concentration.

a Median [range]

b Sample size reduced by 1

c Sample size reduced by 3

d Sample size reduced by 2

e Sample size reduced by 5.